[Corporate Information](index=3&type=section&id=Corporate%20Information) - The report details the company's core management, board members, registered office, Hong Kong and mainland China office addresses, and principal bankers[4](index=4&type=chunk)[6](index=6&type=chunk) [Management Discussion and Analysis](index=5&type=section&id=Management%20Discussion%20and%20Analysis) [Business Overview](index=5&type=section&id=BUSINESS%20OVERVIEW) In H1 2021, the Group's mainland China operations remained stable amid a challenging global environment, achieving significant revenue growth and a narrowed loss Key Performance Indicators for H1 2021 | Indicator | H1 2021 | H1 2020 | Change YoY | | :--- | :--- | :--- | :--- | | **Total Revenue** | HK$324.8 million | HK$260.0 million | +24.9% | | **Loss Attributable to Equity Holders** | HK$32.0 million | HK$69.9 million | -54.2% | | **Bank and Cash Balances (at period end)** | HK$208.6 million | - | - | Revenue Performance by Business Segment | Business Segment | H1 2021 Revenue | H1 2020 Revenue | Change YoY | | :--- | :--- | :--- | :--- | | **Electronic Manufacturing Services (EMS)** | HK$298.0 million | HK$231.2 million | +28.9% | | **Distribution of Communication Products** | HK$23.9 million | HK$15.8 million | +51.3% | | **Real Estate Supply Chain Services** | HK$2.6 million | HK$12.7 million | -79.5% | | **Investment in Securities and Other Assets** | HK$0.3 million | HK$0.3 million | 0% | - The company strategically entered the high-end healthcare services sector by establishing a joint venture in June 2021 to develop the endometrial stem cell business[11](index=11&type=chunk) [Geographical Analysis](index=6&type=section&id=Geographical%20Analysis) The Group's revenue is primarily derived from the European market, with a significant increase in contribution from the US market Revenue Distribution by Geographical Region | Region | H1 2021 Revenue | % of Total Revenue (2021) | % of Total Revenue (2020) | | :--- | :--- | :--- | :--- | | **Major European Countries** | HK$178.0 million | 54.8% | 53.8% | | **The United States** | HK$34.3 million | 10.6% | 6.4% | | **China (including Hong Kong)** | HK$37.7 million | 11.6% | 17.3% | | **Other Countries** | HK$74.7 million | 23.0% | 22.5% | [Financial Highlights](index=6&type=section&id=FINANCIAL%20HIGHLIGHTS) Driven by revenue growth, the Group's gross profit increased while key expenses were controlled, leading to a significant reduction in net loss Key Items in Statement of Profit or Loss | Financial Metric | H1 2021 | H1 2020 | Change YoY | | :--- | :--- | :--- | :--- | | **Revenue** | HK$324.8 million | HK$260.0 million | +24.9% | | **Cost of Sales** | HK$254.2 million | HK$201.5 million | +26.2% | | **Gross Profit** | HK$70.6 million | HK$58.5 million | +20.7% | | **Gross Profit Margin** | 21.7% | 22.5% | -0.8 ppt | | **Selling and Distribution Expenses** | HK$17.0 million | HK$27.6 million | -38.4% | | **Administrative Expenses** | HK$71.7 million | HK$72.6 million | -1.2% | | **Finance Costs** | HK$1.8 million | HK$3.0 million | -40.0% | | **Loss Attributable to Owners** | HK$32.0 million | HK$69.9 million | -54.2% | [Liquidity and Financial Resources](index=8&type=section&id=LIQUIDITY%20AND%20FINANCIAL%20RESOURCES) As of June 30, 2021, the Group maintained a sound financial position with increased cash reserves and an improved gearing ratio Liquidity and Financial Position Indicators (as of June 30, 2021) | Indicator | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Cash and Cash Equivalents** | HK$208.6 million | HK$167.7 million | | **Current Ratio** | 1.6 times | 1.6 times | | **Total Borrowings** | HK$20.6 million | HK$18.6 million | | **Gearing Ratio** | 52.1% | 55.0% | [Capital Structure and Financing Activities](index=9&type=section&id=CAPITAL%20STRUCTURE) The company successfully raised capital through two share placements during the period to fund operations and new business development - On January 11, 2021, the company successfully placed **85.58 million shares** at HK$0.35 per share, raising net proceeds of **HK$29.2 million**[36](index=36&type=chunk) - On June 30, 2021, the company successfully placed **102.7 million shares** at HK$0.224 per share, raising net proceeds of **HK$22.21 million**[37](index=37&type=chunk) - As of June 30, 2021, the total number of issued shares increased to **616,242,570** from 427,958,570 at the end of 2020[35](index=35&type=chunk) [Prospects](index=13&type=section&id=PROSPECTS) The Group is cautiously optimistic about its future, focusing on new growth in high-end healthcare services and leveraging policy changes - The Group has established a joint venture to engage in endometrial stem cell storage and fertility health management, marking a substantial move into the high-end medical field[62](index=62&type=chunk) - Management anticipates that China's **'three-child policy'** will create opportunities in the assisted reproduction and stem cell therapy markets, and the Group will actively integrate resources to capitalize on this trend[62](index=62&type=chunk) [Corporate Governance and Other Information](index=14&type=section&id=Corporate%20Governance%20and%20Other%20Information) [Corporate Governance](index=14&type=section&id=CORPORATE%20GOVERNANCE) The company complied with most Corporate Governance Code provisions but deviated by not separating the Chairman and CEO roles - The company deviated from Code Provision A.2.1 of the Corporate Governance Code, as the roles of **Chairman and Chief Executive Officer were not separated** and were both held by Mr. Lin Dailian[67](index=67&type=chunk)[68](index=68&type=chunk) [Share Option Scheme](index=16&type=section&id=Share%20Option%20Scheme) A new share option scheme was adopted in March 2020, under which over 35 million options were granted during the reporting period Details of Share Options Granted in H1 2021 | Category of Grantee | Name | Number of Options Granted | Exercise Price per Share (HK$) | Date of Grant | | :--- | :--- | :--- | :--- | :--- | | **Director** | Lin Dailian | 5,135,380 | 0.359 | January 28, 2021 | | **Director** | Xia Xiaobing | 5,135,380 | 0.359 | January 28, 2021 | | **Director** | Wang Guozhen | 5,135,380 | 0.359 | January 28, 2021 | | **Employee** | - | 20,265,710 | 0.359 | January 29, 2021 | | **Total** | - | **35,671,850** | - | - | - As of June 30, 2021, there were **35,671,850 outstanding share options** under the new share option scheme[84](index=84&type=chunk) [Interests of Directors and Major Shareholders](index=19&type=section&id=Interests%20and%20Short%20Positions%20of%20the%20Directors%20and%20Chief%20Executives) As of June 30, 2021, three executive directors held long positions through share options, while Power Port Holdings Limited was the largest shareholder Major Shareholders' Interests (as of June 30, 2021) | Name of Shareholder | Number of Shares Held | Percentage of Shareholding | | :--- | :--- | :--- | | Power Port Holdings Limited (Ms. Yang Changrong) | 75,817,000 | 12.30% | | Keywan Global Limited (Mr. He Xiaoming) | 49,500,000 | 8.03% | | Mr. Cao Longbing | 36,358,000 | 5.90% | | Hearts Capital SPC — Hearts SP2 | 35,930,000 | 5.83% | [Condensed Consolidated Financial Statements](index=22&type=section&id=Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Statement of Profit or Loss](index=22&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) For the six months ended June 30, 2021, the company's revenue grew 24.9% year-on-year, leading to a significantly narrowed operating and total loss Summary of Statement of Profit or Loss for H1 2021 | Item (HK$'000) | H1 2021 | H1 2020 | | :--- | :--- | :--- | | **Revenue** | 324,797 | 260,005 | | **Gross Profit** | 70,586 | 58,499 | | **Operating loss** | (28,274) | (61,705) | | **Loss before tax** | (30,060) | (67,762) | | **Loss for the period** | (32,129) | (69,922) | | **Loss attributable to owners of the Company** | (32,042) | (69,918) | | **Basic loss per share (HK cents)** | 7.02 | 20.52 | [Condensed Consolidated Statement of Financial Position](index=24&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2021, the Group's total assets stood at HK$669.3 million, with total equity increasing due to new share issuance Summary of Statement of Financial Position (as of June 30, 2021) | Item (HK$'000) | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total non-current assets** | 141,241 | 145,901 | | **Total current assets** | 528,017 | 511,504 | | **Total assets** | 669,258 | 657,405 | | **Total current liabilities** | 339,328 | 330,549 | | **Total liabilities** | 348,366 | 361,471 | | **Total equity** | 320,892 | 295,934 | [Condensed Consolidated Statement of Cash Flows](index=27&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) In H1 2021, net cash from financing and investing activities offset operating outflows, resulting in a net increase in cash and cash equivalents Summary of Cash Flows for H1 2021 | Item (HK$'000) | H1 2021 | H1 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | (19,969) | (44,801) | | **Net cash from/(used in) investing activities** | 21,342 | (90,957) | | **Net cash from financing activities** | 39,117 | 27,988 | | **Net increase/(decrease) in cash and cash equivalents** | 40,490 | (47,115) | | **Cash and cash equivalents at end of period** | 208,621 | 194,226 | [Notes to the Condensed Financial Statements](index=28&type=section&id=Notes%20to%20the%20Condensed%20Financial%20Statements) [Note 4: Revenue and Segment Information](index=32&type=section&id=4.%20REVENUE%20AND%20SEGMENT%20INFORMATION) The Group's operations are divided into four segments, with Electronic Manufacturing Services (EMS) being the primary contributor to revenue and profit Performance by Business Segment for H1 2021 | Business Segment (HK$'000) | Revenue from external customers | Segment profit/(loss) | | :--- | :--- | :--- | | **Electronic Manufacturing Services (EMS)** | 297,985 | 10,635 | | **Distribution of communication products** | 23,909 | 310 | | **Investment in securities and other assets** | 340 | (17,257) | | **Real estate supply chain services** | 2,563 | (21,860) | | **Total** | **324,797** | **(28,172)** | [Note 23: Share Capital](index=49&type=section&id=23.%20SHARE%20CAPITAL) During the period, the company's issued and fully paid-up share capital increased following the placement of 188,284,000 new shares - On January 11, 2021, the company placed **85,580,000 new shares**, raising net proceeds of approximately **HK$29.35 million**[281](index=281&type=chunk) - On June 30, 2021, the company placed **102,704,000 new shares**, raising net proceeds of approximately **HK$22.32 million**[282](index=282&type=chunk) [Note 27: Events After the Reporting Period](index=52&type=section&id=27.%20EVENTS%20AFTER%20THE%20REPORTING%20PERIOD) Subsequent to the reporting period, the Group completed the disposal of its entire equity interest in one associate company in July 2021 - On March 23, 2021, the Group entered into agreements to dispose of its entire equity interests in associate companies Zhan Ju and Rong Shu[300](index=300&type=chunk) - The disposal of Zhan Ju was completed on **July 5, 2021**, after which the Group lost significant influence over the company[301](index=301&type=chunk) [Information for Investors](index=53&type=section&id=Information%20for%20Investors) - The company is listed on The Stock Exchange of Hong Kong Limited with the stock code 1143[310](index=310&type=chunk)

P LAIM Link-Asia International MedTech Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司 (formerly known as Link-Asia International Co. Ltd.) (前稱環亞國際實業有限公司) (incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司) (Stock Code 股份代號：1143) A CONTENTS 目錄 Corporate Information 公司資料 2 Financial Highlights 財務摘要 4 Chairman's Statement 主席報告書 5 Management Discussion and Analysis 管理層討論及分析 7 Corporate Governance Report 企業管治報告 25 Biographical Details of Directors 董事履歷詳情 40 Environmental, Soc ...

Financial Performance - For the six months ended June 30, 2020, the Group's revenue from continuing operations decreased by approximately HK$32.7 million, from approximately HK$292.7 million in 2019 to HK$260.0 million in 2020[7]. - The loss attributable to equity holders of the Company for the Period was approximately HK$69.9 million, representing an increase of 24.5% compared to a loss of approximately HK$56.2 million for the prior period[7]. - Total revenue from continuing operations for the period was approximately HK$260.0 million, a decrease of about 11.2% from HK$292.7 million in 2019[17]. - Loss for the period was HK$69,922,000, compared to a loss of HK$54,539,000 in the same period of 2019, representing a 28.3% increase in loss[148]. - Gross profit for the six months ended June 30, 2020, was HK$58,499,000, down from HK$59,724,000 in 2019, indicating a slight decline of 2.1%[143]. - Total comprehensive loss for the period was HK$87,116,000, compared to HK$44,546,000 in the same period of 2019, indicating a significant increase in overall loss[148]. Revenue Breakdown - The EMS business contributed approximately HK$231.2 million in revenue during the Period, down from HK$269.1 million in 2019[7]. - Revenue from the Distribution of Communication Products was approximately HK$15.8 million, a decrease from HK$17.9 million in 2019[7]. - The Real Estate Supply Chain Services segment contributed approximately HK$12.7 million in revenue for the Period, compared to nil in 2019[9]. - Revenue from major European countries totaled approximately HK$139.8 million, accounting for approximately 53.8% of total revenue, compared to 51.3% in 2019[12]. - The U.S. market contributed approximately HK$16.5 million, representing about 6.4% of total revenue, down from 13.2% in 2019[12]. - Revenue from the PRC (including Hong Kong) was approximately HK$45.0 million, accounting for about 17.3% of total revenue, an increase from 15.7% in 2019[12]. Expenses and Costs - Selling and distribution expenses from continuing operations were approximately HK$27.6 million in 2020, accounting for 10.6% of the Group's revenue, up from 5.6% in 2019[19]. - Administrative expenses from continuing operations decreased to approximately HK$72.6 million in 2020, representing 27.9% of revenue, compared to 26.3% in 2019[19]. - Other income from continuing operations decreased to HK$5.8 million, down from HK$6.8 million in 2019, primarily due to COVID-19 related impacts[17]. - Finance costs from continuing operations were approximately HK$3.0 million in 2020, representing 1.2% of revenue, a slight decrease from 1.1% in 2019[19]. Cash and Liquidity - As of June 30, 2020, the Group maintained bank and cash balances totaling HK$194.2 million, down from HK$241.4 million as of December 31, 2019[7]. - The Group's current ratio was 1.7 times as of 30 June 2020, down from 1.9 times in 2019, with cash and cash equivalents amounting to approximately HK$194.2 million[21]. - Cash and cash equivalents at the end of the period were HK$194,226,000, down from HK$375,348,000 at the end of June 2019[159]. Impact of COVID-19 - The Group's operations were significantly impacted by COVID-19, leading to production and delivery challenges[7]. - The board anticipates improvement in the real estate supply chain services segment as COVID-19 vaccines and treatments progress[13]. - The major economies experienced the largest quarterly contraction in decades during the first half of 2020 due to COVID-19 disruptions[66]. Share Capital and Equity - The total number of issued shares of the Company as of 30 June 2020 was 356,718,570, following a share consolidation[23]. - The share capital increased from HK$5,945,000 to HK$7,134,000, an increase of approximately 20.0%[153]. - Total equity attributable to owners of the Company decreased from HK$411,013,000 to HK$365,899,000, a decline of about 10.9%[153]. Investments and Acquisitions - The Group has started to expand into real estate advisory and purchase services in Southeast Asia and Pan Asia markets since the second half of 2019[7]. - The company made a deposit of HK$18,000,000 for exclusive agency rights in a Thailand real estate project[159]. - The company has no specific plans for material investments or capital assets as of June 30, 2020[44]. Governance and Compliance - The Company has complied with the Listing Rules regarding the composition of the Board and Audit Committee following the appointment of an independent non-executive Director on April 24, 2020[84]. - The company does not recommend the payment of an interim dividend for the period, consistent with 2019 where no dividend was paid[92]. - The Company’s corporate governance practices are in compliance with the relevant regulations and standards[119].

Financial Performance - For the year ended December 31, 2019, the Group reported revenue of HK$ 629.9 million, a decrease of 7.6% from HK$ 681.5 million in 2018[19]. - The loss for the year was HK$ 179.3 million, compared to a loss of HK$ 49.3 million in 2018, indicating a significant decline in profitability[19]. - Loss attributable to owners of the Company was HK$ 171.7 million, up from HK$ 58.0 million in the previous year[19]. - The Group's total revenue from continuing operations for the year was approximately HK$629.9 million, a decrease from HK$681.5 million in 2018, representing a decline of about 7.3%[33]. - Gross profit from continuing operations amounted to approximately HK$135.8 million, down from HK$147.3 million in 2018, indicating a decrease of approximately 7.9%[33]. - The loss attributable to owners of the Company was approximately HK$171.8 million, compared to a loss of HK$58.0 million in 2018, reflecting a significant increase in losses[33]. - Revenue from the EMS segment decreased by approximately 6.5% to HK$582.5 million, while the Distribution of Communications Products segment saw a decline of approximately 16.6% to HK$36.5 million[49]. - The Group's finance costs increased to approximately HK$6.8 million in 2019 from HK$2.8 million in 2018, representing 1.1% and 0.4% of revenue from continuing operations, respectively[60][65]. Asset and Liability Management - The Group's total assets decreased to HK$ 734.8 million from HK$ 930.9 million, while total liabilities slightly decreased to HK$ 323.9 million from HK$ 348.0 million[19]. - As of December 31, 2019, the Group had bank and cash balances totaling approximately HK$241.4 million, down from HK$354.2 million in 2018, indicating a decrease of about 31.8%[36]. - The current ratio of the Group was 1.9 times as of December 31, 2019, down from 2.15 times in 2018, indicating a slight decline in liquidity[69]. - The gearing ratio increased to 44.1% as of December 31, 2019 from 37.4% in 2018, calculated based on total liabilities divided by total assets[71][75]. Strategic Developments - The Group officially changed its name to Link-Asia International Co. Ltd. on November 20, 2019, as part of its future development strategy[23]. - The Group has begun to explore opportunities in the real estate supply chain service business in Southeast Asia since the second half of 2019, targeting local development and asset allocation needs[23]. - The Group has shifted its business focus towards the Southeast Asia real estate supply chain, leveraging its network to identify high-quality projects since the second half of 2019[32]. - The Group aims to consolidate resources and seek new business opportunities to provide reasonable returns to shareholders amidst challenging economic conditions[28]. Market Conditions - China's GDP growth fell to 6.1% in 2019, the lowest since 1990, impacting the Group's export business and overall performance[22]. - The Group will continue to monitor negative impacts from geopolitical conflicts and seek quality investment opportunities for sustainable development[22]. - The Group's operating environment has been significantly affected by the COVID-19 outbreak, leading to market volatility[117]. - The Group anticipates a severe contraction in the economy due to the ongoing pandemic[119]. Governance and Compliance - Mr. Wong Chun Hung resigned as an independent non-executive Director on 12 August 2019, leading to a temporary non-compliance with Listing Rules regarding the minimum number of independent non-executive Directors[131]. - The Company appointed Mr. Li Huiwu as an independent non-executive Director and chairman of the Audit Committee on 14 October 2019, restoring compliance with Listing Rules 3.10(1), 3.10A, and 3.21[133]. - The Board currently consists of three Executive Directors and three Independent Non-executive Directors, with the latter accounting for over one-third of the Board[145]. - The Company has adopted the Model Code for Securities Transactions by Directors, with all Directors confirming compliance throughout the year ended 31 December 2019[134]. - The Company has complied with Listing Rules 3.10(1) and (2) since the Listing Date, maintaining a balanced and independent Board composition[145]. Risk Management - The Group is exposed to market risks, including fluctuations in foreign exchange rates, interest rates, and equity prices, and currently does not have a foreign currency hedging policy[101][102]. - The Group is closely monitoring liquidity risk by maintaining adequate cash levels to finance operations[109]. - The Group is managing interest rate risk dynamically to ensure cost-effective risk management[108]. - The Group faces manpower and retention risks, and will provide attractive remuneration packages to retain key personnel[111]. Employee and Community Engagement - The Group had approximately 1,400 employees as of 31 December 2019, offering competitive remuneration packages and training programs to attract and retain talent[92]. - The Group is committed to maintaining high environmental and social standards, encouraging participation in community activities, and complying with environmental laws[94][95].

HEALTHCARE 华 | 夏 | 健 | 康 China Healthcare Enterprise Group Limited 華夏健康產業集團有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1143 INTERIM REPORT 中期報告 N Z M N H M N a a marker t H B Contents 目錄 Corporate Information 公司資料 2 | --- | --- | --- | |-----------------------------------------------------------------------------------|-----------------------------------|-------| | | | | | Management Discussion and Analysis | 管理層討論及分析 | 4 | | Corporate Governance and O ...

H HEALTHCARE 华 | 夏 | 健 | 康 China Healthcare Enterprise Group Limited 華夏健康產業集團有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1143 2018 #* CONTENTS 目錄 79 80 82 83 87 222 224 Profit or Loss 綜合損益表 | --- | --- | --- | |------------------------------------------------------------------|-------|-----------------------------------------------------------------| | Corporate Information | 2 | Consolidated Statement of | | 公司资料 | | Profit or Loss and Other | | Finan ...